Ontology highlight
ABSTRACT: Background
Strict eligibility criteria for patient enrollment in phase III trials raise questions regarding generalization to ineligible patients. We evaluated whether pivotal phase III trials of immune checkpoint blockades (ICBs) represent the overall population of non-small cell lung cancer (NSCLC) patients.Methods
We reviewed the inclusion and exclusion criteria of three phase III trials (CheckMate057, CheckMate017, and KEYNOTE-010). Stage IIIB or IV NSCLC patients diagnosed from 2011 to 2013 at Seoul National University Hospital (cohort 1) were reviewed. We also analyzed the criteria in 53 patients with NSCLC who were treated with nivolumab or pembrolizumab as routine practice (cohort 2).Results
Among the 715 patients in cohort 1, 499 (69.9%) were ineligible for
SUBMITTER: Yoo SH
PROVIDER: S-EPMC6456815 | biostudies-literature | 2018 Jun
REPOSITORIES: biostudies-literature